Arca
Skip to content
Tools
Tools

CHRM4: Muscarinic acetylcholine receptor M4

The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on CHRM4, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Xanomeline

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        XanomelineApprovedKaruna TherapeuticsSmall moleculeAgonistMuscarinic acetylcholine receptor M4 agonist28

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        A Prospective, Observational, Single-Arm, Multicenter Real-World Study Evaluating the Treatment Pattern, Safety and Effectiveness of Xanomeline and Trospium Chloride Capsules (KarXT) in the Treatment of Chinese Adult Participants With SchizophreniaXanomeline—Not yet recruitingZai Lab (Shanghai) Co., Ltd.Sep 3, 2026
        Long-Term Real-World Safety of Cobenfy in Adults With SchizophreniaXanomeline—Active, not recruitingBristol-Myers SquibbAug 24, 2026
        Human Cognition During Surgery: Stimulation-based and Cholinergic ModulationXanomelineEarly phase 1Not yet recruitingUniversity of Texas Southwestern Medical CenterJul 23, 2026
        Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaXanomelinePhase 3RecruitingKaruna Therapeutics, Inc., a Bristol Myers Squibb companyJul 7, 2026
        Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy VolunteersXanomelinePhase 4RecruitingKaruna Therapeutics, Inc., a Bristol Myers Squibb companyJul 2, 2026
        The Impact of Cobenfy Maintenance on Cocaine's EffectsXanomelinePhase 1 / Phase 2RecruitingJoshua A. Lile, Ph.D.Jun 3, 2026
        A PET/MRI Study of Cobenfy on Dopamine Transmission in SchizophreniaXanomelinePhase 1 / Phase 2RecruitingNew York State Psychiatric InstituteFeb 20, 2026
        A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsXanomelinePhase 3RecruitingKaruna Therapeutics, Inc., a Bristol Myers Squibb companyFeb 20, 2026

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Peptic ulcer disease0.50
        • Cardiac arrhythmia0.46
        • Psychotic disorder0.37
        • Bipolar I disorder0.37
        • Agitation0.37

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1821, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P08173, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.